A drug originally used to boost the immune system is showing promise as a potential new treatment for lupus, joint Monash University and Peking University research published today shows. Lupus is an autoimmune disease, where the immune system attacks the body’s own organs and tissues.
An international team of scientists from Australia and China have, for the first time, shown in a study published in Nature Medicine, that a natural immune system protein called IL-2 can help restore balance to the overactive immune system of lupus patients. The drug could soon be rolled out for clinical trials in lupus treatment.
Monash Biomedicine Discovery Institute researcher, Dr Di Yu and Professor Zhanguo Li from Peking University People’s Hospital in China co-led the study.
Dr Yu said he hoped the drug could be approved as a lupus treatment within a handful of years.
“This drug, which can help the immune system fight against cancer, was approved in the 1990s but is not commonly used now. We’re now using this drug for a different purpose, based on our new knowledge of the immune system,” Dr Yu said.
“The amount we tested for treating lupus is much less than the dose used in treating cancers. We observed the treatment was safe and showed promising results, so there’s reason to believe formal trials could begin almost immediately,” he said.
Dr Yu said lupus could be a serious disease, and that it hadn’t been able to be treated in a very satisfactory way in the past.
IL-2 is a protein that regulates the activity of white blood cells, which are an important part of the immune system that protect the body against infections. In cancer therapy, patients are given large doses of IL-2 to stimulate their immune system but, paradoxically, the low dose IL-2 given to lupus sufferers in this study actually supressed the overactive part of their immune system that attacks their body. The research also showed the “self-checking” part of the immune system that prevents an overactive immune response, called regulatory T cells, increased after IL-2 treatment.
Professor Eric Morand, fellow Monash University researcher on the study and founder of the Asia Pacific Lupus Collaboration, said that in this study, IL-2 was given to people whose lupus wasn’t responding well to standard treatments.
“The real promise of this treatment is that it calms the hyperactive immune system through multiple mechanisms, which is very important as this new therapy may be effective for many patients,” Professor Morand said.
”As the drug has been on the market for some time for other diseases, it can be rapidly put into formal trials for lupus treatment right away.”
Learn more: Promising new treatment for lupus on the horizon
The Latest on: Lupus
via Google News
The Latest on: Lupus
- SMALL CAP MOVERS: ImmuPharma nearly trebles in value as US deal resurrects flagship lupus drugon November 29, 2019 at 8:32 am
AIM saw a resurrection this week as small cap biotech ImmuPharma secured a deal worth almost $100million for Lupuzor, its treatment for the autoimmune disease lupus. US speciality drugs group Avion ...
- Global Systemic Lupus Erythematosus (SLE) Market Insights, Epidemiology, and Market Forecasts 2017-2028 - ResearchAndMarkets.comon November 28, 2019 at 1:28 am
DUBLIN--(BUSINESS WIRE)--The "Systemic Lupus Erythematosus (SLE) - Market Insights, Epidemiology, and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
- ImmuPharma licenses lupus drug Lupuzor to Avion in the United Stateson November 27, 2019 at 11:53 pm
British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company ...
- Scarcity of lupus assays in developing countries limit utility of international criteria, trialson November 27, 2019 at 8:40 am
ATLANTA — Limited access to supportive laboratory assays in developing countries significantly reduces the diagnostic utility of the ACR/EULAR criteria for systemic lupus erythematosus, which relies ...
- New Study Finds Glucocorticoid Use Contributes to Organ Damage in People with Lupuson November 27, 2019 at 7:01 am
Glucocorticoid use was found to contribute to damage accrual in people with systemic lupus erythematosus independently of the presence of clinical signs or serological disease activity. In a cohort of ...
- Lupus Research Alliance 2019 Breaking Through Gala Raises $3 Million for Lupus Researchon November 26, 2019 at 4:08 pm
NEW YORK, Nov. 26, 2019 /PRNewswire/ -- The Lupus Research Alliance (LRA) 2019 Breaking Through Gala gathered more than 600 members of the global lupus community last night to raise $3 million, all of ...
- Lupus algorithm, pediatric psoriasis guidelines lead dermatology newson November 26, 2019 at 9:12 am
Clinical specialty setting and geographic region can affect the diagnosis timing of psoriatic arthritis, disease management and disease burden, according to researchers in a Healio Dermatology story ...
- Research Finds Kidney Transplant Successfully Improves Survival Rates in People with Lupus Nephritison November 26, 2019 at 7:25 am
A recent study underscores the effectiveness of kidney transplants in people with lupus nephritis (LN) and the importance of getting those on dialysis on the kidney transplant list as early as ...
- A New Hope: Exploring Novel Approaches to Lupuson November 26, 2019 at 3:19 am
Lupus is a chronic autoimmune disease that causes inflammation, pain and damage to the skin, joints, brain and kidneys. Lupus is a complex disease; each patient has a different combination of symptoms ...
- Novel Antibody Looks Promising in Lupus Nephritison November 25, 2019 at 6:06 pm
WASHINGTON, DC — A novel antibody, obinutuzumab (Genentech-Roche), enhances renal responses in patients with lupus nephritis, through more complete B-cell depletion, compared with standard ...
via Bing News